These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19504141)

  • 21. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
    Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Barbieri L; Pergolini P; Verdoia M; Rolla R; Nardin M; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Vascul Pharmacol; 2016 Apr; 79():11-15. PubMed ID: 26518440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study.
    Saw J; Madsen EH; Chan S; Maurer-Spurej E
    J Am Coll Cardiol; 2008 Dec; 52(23):1826-1833. PubMed ID: 19038679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
    Thromb Res; 2005; 116(6):491-7. PubMed ID: 16181985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the platelet function analyzer (PFA-100).
    Dyszkiewicz-Korpanty A; Olteanu H; Frenkel EP; Sarode R
    Platelets; 2007 Nov; 18(7):491-6. PubMed ID: 17852774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.
    Gajos G; Rostoff P; Undas A; Piwowarska W
    J Am Coll Cardiol; 2010 Apr; 55(16):1671-8. PubMed ID: 20394870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease.
    Perneby C; Wallén NH; Hofman-Bang C; Tornvall P; Ivert T; Li N; Hjemdahl P
    Thromb Haemost; 2007 Dec; 98(6):1316-22. PubMed ID: 18064330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction.
    Matetzky S; Fefer P; Shenkman B; Varon D; Savion N; Hod H
    Am J Cardiol; 2008 Sep; 102(5):524-9. PubMed ID: 18721506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Retention Index Test Homburg (RTH-II): Response to clopidogrel and comparison with aggregometry and CD62P-expression.
    Klinkhardt U; Wenzel E; Harder S
    Platelets; 2006 Feb; 17(1):42-8. PubMed ID: 16308186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.
    Hochholzer W; Trenk D; Fromm MF; Valina CM; Stratz C; Bestehorn HP; Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2010 Jun; 55(22):2427-34. PubMed ID: 20510210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement.
    Trenk D; Hochholzer W; Frundi D; Stratz C; Valina CM; Bestehorn HP; Büttner HJ; Neumann FJ
    Thromb Haemost; 2008 Jan; 99(1):174-81. PubMed ID: 18217151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention.
    Claeys MJ; Van Der Planken MG; Michiels JJ; Vertessen F; Dilling D; Bosmans JM; Vrints CJ
    Blood Coagul Fibrinolysis; 2002 Jun; 13(4):283-8. PubMed ID: 12032392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet function in clopidogrel-treated patients with acute coronary syndrome.
    Sibbing D; von Beckerath O; Schömig A; Kastrati A; von Beckerath N
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):335-9. PubMed ID: 17473574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin.
    Dropinski J; Jakiela B; Sanak M; Wegrzyn W; Biernat M; Dziedzina S; Plutecka H; Szczeklik A
    Thromb Haemost; 2007 Jul; 98(1):201-9. PubMed ID: 17598014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.
    Simon T; Bhatt DL; Bergougnan L; Farenc C; Pearson K; Perrin L; Vicaut E; Lacreta F; Hurbin F; Dubar M
    Clin Pharmacol Ther; 2011 Aug; 90(2):287-95. PubMed ID: 21716274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial.
    Ntalas IV; Kalantzi KI; Tsoumani ME; Vakalis JN; Vasilakopoulos V; Vardakis K; Vemmos KN; Voukelatou M; Giannakoulas G; Giatrakos I; Giogiakas V; Goumas G; Dimoulis N; Draganigos A; Efthimiadis I; Thoma M; Kazakos E; Kipouridis N; Konstantinou S; Bourdakis A; Nikolopoulos D; Peltekis L; Prokopakis N; Sinteles I; Stroumbis CS; Terzoudi K; Tsilias K; Xaraktsis I; Charmpas C; Hatziathanasiou G; Christogiannis Z; Panagiotakos DB; Goudevenos JA; Tselepis AD
    Curr Vasc Pharmacol; 2015; 13(6):809-18. PubMed ID: 25782408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of clopidogrel resistance in ischemic stroke patients.
    Fukuoka T; Furuya D; Takeda H; Dembo T; Nagoya H; Kato Y; Deguchi I; Maruyama H; Horiuchi Y; Tanahashi N
    Intern Med; 2011; 50(1):31-5. PubMed ID: 21212570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced antiplatelet effects of clopidogrel plus acetylsalicylic acid compared with acetylsalicylic acid alone or combined with extended-release dipyridamole in healthy volunteers.
    Caplain H
    Cerebrovasc Dis; 2005; 19(4):214-9. PubMed ID: 15703464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study.
    Collet JP; Silvain J; Landivier A; Tanguy ML; Cayla G; Bellemain A; Vignolles N; Gallier S; Beygui F; Pena A; Montalescot G
    Circulation; 2008 Sep; 118(12):1225-33. PubMed ID: 18765393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.
    Bierend A; Rau T; Maas R; Schwedhelm E; Böger RH
    Br J Clin Pharmacol; 2008 Apr; 65(4):540-7. PubMed ID: 17995973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.